METHODS: We examined, in samples (Mage = 16.4, SD = 1.2), of ever-medicated adolescents at risk for ADHD (n = 18; 72% boys), medication-naïve adolescents at risk for ADHD (n = 15, 67% boys), and adolescents not at risk for ADHD (n = 31, 61% boys) matched for chronological age and controlling for non-ADHD pharmacotherapy, whether ADHD pharmacotherapy modulates the association between NREM SWA and ADHD risk in home sleep.
RESULTS: Findings indicated medication-naïve adolescents at risk for ADHD exhibited greater first sleep cycle and entire night NREM SWA than both ever-medicated adolescents at risk for ADHD and adolescents not at risk for ADHD and no difference between ever-medicated, at-risk adolescents, and not at-risk adolescents.
CONCLUSIONS: Results support atypical cortical maturation in medication-naïve adolescents at risk for ADHD that appears to be normalized by ADHD pharmacotherapy in ever-medicated adolescents at risk for ADHD. Greater NREM SWA may reflect a compensatory mechanism in middle-later adolescents at risk for ADHD that normalizes an earlier occurring developmental delay.
方法:我们检查了,在样本中(Mage=16.4,SD=1.2),有ADHD风险的青少年(n=18,72%的男孩),有ADHD风险的青少年(n=15,67%的男孩),和没有多动症风险的青少年(n=31,61%的男孩)与实际年龄相匹配,是否控制非ADHD药物治疗,ADHD药物治疗调节NREMSWA与家庭睡眠中ADHD风险之间的关联。
结果:研究结果表明,与曾经服用过药物的有ADHD风险的青少年和没有ADHD风险的青少年相比,未服用药物的青少年表现出更大的第一睡眠周期和整晚的NREMSWA,有风险的青少年和没有风险的青少年。
结论:结果支持存在ADHD风险的未用药青少年的非典型皮质成熟,在存在ADHD风险的曾用药过的青少年中,ADHD药物治疗似乎已恢复正常。更大的NREMSWA可能反映了处于ADHD风险的中晚期青少年的补偿机制,该机制使早期发生的发育延迟正常化。